p XSC
Latest Information Update: 26 Nov 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Protein kinase A inhibitors; Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Feb 2000 Profile reviewed but no significant changes made
- 10 Apr 1997 Preclinical development for Cancer in USA (Unknown route)